Jay Backstrom, Scholar Rock CEO
October 7, 2024 11:47 AM EDT
R&D

Schol­ar Rock claims suc­cess in Phase 3 spinal mus­cu­lar at­ro­phy study, stock soars

Lei Lei Wu

News Reporter

Schol­ar Rock an­nounced its ex­per­i­men­tal add-on treat­ment for spinal mus­cu­lar at­ro­phy sig­nif­i­cant­ly im­proved mo­tor func­tion com­pared to place­bo at one year …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

TRENDING NOW

Spe­cial re­port 2024: Meet 20 women break­ing new ground in bio­phar­ma R&D

Pfiz­er tar­get­ed by ac­tivist, fol­low­ing post-pan­dem­ic stum­bles — re­ports

As­traZeneca makes an­oth­er car­dio deal, bet­ting $100M on Chi­na com­pa­ny’s lipid drug

Ju­do Bio launch­es with $100M for kid­ney-tar­get­ed siR­NA ther­a­pies

Gala­pa­gos in­vestor gets board seat; OnKure com­pletes merg­er with Re­neo

No­vo and Vi­a­tris set­tle Ozem­pic patent suit as gener­ic en­try date re­mains un­known

A service from the Financial Times